The market correctly sees biology's potential but often misunderstands its timeline. Even with AI, biology is fundamentally harder and slower than software. Daniel Fero warns this mismatch in "tempo" expectations leads to over-funding hype cycles while under-funding foundational companies that are simply moving at the pace required for rigorous biological R&D.

Scientist-founders often believe one more experiment will prove their hypothesis. To succeed as a CEO, they must shift from scientific curiosity to ruthless capital discipline, killing unviable programs and building a team that challenges ideas, not just executes them.

Since most biotech programs fail (as few as 1 in 10 succeed), a company's survival depends on running a portfolio of multiple programs simultaneously. This requires the discipline to quickly terminate unsuccessful projects and the foresight to have subsequent programs already underway.

While biotech cannot easily replicate tech's rapid iteration cycles due to high costs and long feedback loops, it can adopt the capital efficiency model of tech seed investing. The strategy is to kill flawed projects quickly and cheaply, ensuring that when you lose, you lose small.

Unlike software startups that can "fail fast" and pivot cheaply, a single biotech clinical program costs tens of millions. This high cost of failure means the industry values experienced founders who have learned from past mistakes, a direct contrast to Silicon Valley's youth-centric culture.

The fastest way to de-risk a biotech concept is to actively try to 'kill' it. By pitching to experts and seeking critical feedback in competitions, founders can expose fatal flaws early. If the idea is invalidated, it saves years of wasted effort; if it survives, it's significantly stronger.

The transition from academic scientist to biotech CEO involves a critical mindset shift. In academia, ideas and knowledge are the primary capital. In the resource-intensive biotech world, time is the scarcest and most valuable asset, demanding parallel execution.

Given that 90% of drugs fail in the clinic, the most critical innovation isn't a single brilliant idea. It's building a company with the operational efficiency and financial runway to conduct all ten necessary experiments to find the one that will succeed.

Founders must balance scientific conviction with market feedback. Kulkarni shares that his team abandoned pursuing certain indications that, while scientifically sound, failed to gain investor traction. This shows the critical need to pivot based on market signals, not just internal belief, to ensure continued funding and support.